RTP Mobile Logo
Select Publications

Antonia SJ et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379(24):2342-50. Abstract

Antonia SJ et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017;377:1919-29. Abstract

Bradley JD et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 Study. Lancet Oncol 2015;16(2):187-99. Abstract

Brahmer JR et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36(17):1714-1768. Abstract

Butts C et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15(1):59-68. Abstract

Chansky K et al. The IASLC Lung Cancer Staging Project: External validation of the revision of the TNM stage groupings in the eighth edition of the TNM Classification of Lung Cancer. J Thorac Oncol 2017;12(7):1109-21. Abstract

Chen VW et al. Analysis of stage and clinical/prognostic factors for lung cancer From SEER registries: AJCC staging and collaborative stage data collection system. Cancer 2014;120:3781-92. Abstract

Detterbeck FC et al.The Eighth Edition Lung Cancer Stage Classification. Chest 2017;151(1):193-203. Abstract

Durm G et al. Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. ASCO 2018;Abstract 8500.

Gray JE et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC — Update from PACIFIC. J Thorac Oncol 2020;15(2):288-93. Abstract

Hanna et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and US Oncology. J Clin Oncol 2008;26(35):5755-60. Abstract

Herbst RS et al. Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. ASCO 2020;Abstract LBA5.

Jabbour SK et al. Prospective phase I multi-institutional trial of PD-1 blockade with pembrolizumab during concurrent chemoradiation for locally advanced, unresectable non-small cell lung cancer. ASCO 2019;Abstract 8511.

June CH et al. Is autoimmunity the Achilles' heel of cancer immunotherapy? Nat Med 2017;23(5):540-547. Abstract

Kelly K et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26(15):2450-6. Abstract

Lisberg AE et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) naïve patients with advanced NSCLC. ASCO 2018;Abstract 9014.

Naidoo J et al. Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC). ASCO 2020;Abstract 9048.

PACIFIC-2: A phase III, randomized, placebo-controlled, double-blind, multi-center, international study of durvalumab given concurrently with platinum-based chemoradiation therapy in patients with locally advanced, unresectable NSCLC (stage III). NCT03519971

Siegel RL et al. Cancer statistics, 2019. CA Cancer J Clin 2019;69(1):7-34. Abstract

Sita T et al. Multi-institutional study of pneumonitis after treatment with durvalumab and chemoradiotherapy for non-small cell lung cancer. IASLC North America 2019. No abstract available

Vansteenkiste J et al. PACIFIC subgroup analysis: Pneumonitis in stage III, unresectable NSCLC patients treated with durvalumab vs placebo after CRT. WCLC 2018;Abstract MA05.02.

Vokes EE et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007;25(13):1698-704. Abstract

Wani SQ et al. Radiation therapy and Its effects beyond the primary target: An abscopal effect. Cureus 2019;11(2):e4100. Abstract